AI English summary of an SEC filing — figures as filed
Viatris VTRSViatris said it reported total revenues of $14.7 Billion for 2024 full year, U.S. GAAP net loss of $(634) Million, adjusted EBITDA of $4.7 Billion and adjusted EPS of $2.65 per share. The company said total revenues, adjusted EBITDA and adjusted EPS met its 2024 outlook, and free cash flow exceeded its outlook.
Key points
AI summaryViatris said it reported total revenues of $14.7 Billion for 2024 full year, U.S. GAAP net loss of $(634) Million, adjusted EBITDA of $4.7 Billion and adjusted EPS of $2.65 per share. The company said total revenues, adjusted EBITDA and adjusted EPS met its 2024 outlook, and free cash flow exceeded its outlook.
The company said U.S. GAAP net cash provided by operating activities for 2024 was $2.3 Billion and free cash flow was $2.0 Billion, including about $650 Million of transaction-related costs. It said it repaid $3.7 Billion of debt in 2024 and ended the year with a total gross leverage ratio of 2.9x.
The company said it received a warning letter and import alert from the U.S. Food and Drug Administration (FDA) for its Indore facility on December 2024, and that the import alert affects 11 products. It estimated the negative impact on total revenues for 2025 at about $500 million and on adjusted EBITDA at about $385 million.
Viatris provided 2025 guidance of total revenues of $13,500 to $14,000 (in millions), adjusted EBITDA of $3,900 to $4,200 (in millions) and free cash flow of $1,800 to $2,200 (in millions). It also said it will prioritize capital return in 2025, including planned share repurchases of $500 Million to $650 Million.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Viatris Reports 2024 Revenue of $14.7 Billion, Net Loss of $(634) Million
Viatris said it reported total revenues of $14.7 Billion for 2024 full year, U.S. GAAP net loss of $(634) Million, adjusted EBITDA of $4.7 Billion and adjusted EPS of $2.65 per share. The company said total revenues, adjusted EBITDA and adjusted EPS met its 2024 outlook, and free cash flow exceeded its outlook.
Source · Based on the filing body and exhibits
Viatris Reports 2024 Operating Cash Flow of $2.3 Billion, Debt Repayment of $3.7 Billion
The company said U.S. GAAP net cash provided by operating activities for 2024 was $2.3 Billion and free cash flow was $2.0 Billion, including about $650 Million of transaction-related costs. It said it repaid $3.7 Billion of debt in 2024 and ended the year with a total gross leverage ratio of 2.9x.
Source · Based on the filing body and exhibits
Indore Facility FDA Warning Letter and Import Alert, and 2025 Impact Estimate
The company said it received a warning letter and import alert from the U.S. Food and Drug Administration (FDA) for its Indore facility on December 2024, and that the import alert affects 11 products. It estimated the negative impact on total revenues for 2025 at about $500 million and on adjusted EBITDA at about $385 million.
Source · Based on the filing body and exhibits
Viatris 2025 Outlook and Plan for $500 Million to $650 Million in Share Repurchases
Viatris provided 2025 guidance of total revenues of $13,500 to $14,000 (in millions), adjusted EBITDA of $3,900 to $4,200 (in millions) and free cash flow of $1,800 to $2,200 (in millions). It also said it will prioritize capital return in 2025, including planned share repurchases of $500 Million to $650 Million.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…